Use of pramipexole in neuropsychiatry
Department of Psychiatry, School of Medicine, University of Zambia (UNZA).
World Journal of Advanced Research and Reviews, 2020, 07(02), 082-088
Article DOI: 10.30574/wjarr.2020.7.2.0283
Publication history:
Received on 28 July 2020; revised on 05 August 2020; accepted on 09 August 2020
Abstract:
Parkinson’s disease (PD) is a progressive neurological disorder characterized by a large number of motor and non-motor features that can impact on function to a variable degree. The syndrome of parkinsonism is recognized, which can become apparent with akinetic rigid disorders in other brain injuries and medication-induced parkinsonism. Genetic mutations or variants, neuroimaging abnormalities and other tests are potential biomarkers that may improve diagnosis and allow the identification of persons at risk. This literature review describes pathogenesis and clinical characteristics of PD with emphasis on modern treatment and possibilities of dopamine agonists, especially pramipexole. During pramipexole treatment of the patients with the early and late stages of PD, we can observe the reduction of expression of cognitive and affective (mood) disorders, the improvement of the quality of life and social functioning.
Keywords:
Parkinson’s disease; Neurodegenerative disease; Neuropsychiatry; Psychopharmacology; Pramipexole; Depression
Full text article in PDF:
Copyright information:
Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0